Afinitor licensed for pancreatic tumours

Dosing is the same for all current indications: 10mg once daily
Dosing is the same for all current indications: 10mg once daily

Afinitor (everolimus) is now indicated for the treatment of advanced pancreatic neuroendocrine tumours in patients with unresectable or metastatic disease.

In the randomised, double-blind study, RADIANT-3 (n=410), median progression-free survival more than doubled with everolimus compared with placebo (11.0 vs 4.6 months).

Afinitor is also indicated for use in advanced renal cell carcinoma which has progressed during or after VEGF-targeted therapy. In addition, Novartis are launching everolimus as Votubia for the treatment of astrocytoma.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases